Neurologic complications of leukemia

Current Opinion in Neurology

Volumn 15, Issue 6, 2002, Pages 691-699

  Demopoulos, Alexis ^a   DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Leptomeningeal metastasis; Leukemia; Leukoencephalopathy; Neurologic complications of cancer

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIBIOTIC AGENT; ANTITHROMBIN; ASPARAGINASE; CYTARABINE; FIBRINOGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; INTERFERON; LIPOPROTEIN A; METHOTREXATE; PROCOAGULANT; PROTEIN C; PROTEIN S; RETINOIC ACID; TACROLIMUS; THROMBOMODULIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BONE MARROW TRANSPLANTATION; BRAIN HEMORRHAGE; BRAIN INFECTION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CEREBRAL SINUS THROMBOSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOCRINE DISEASE; GROWTH RETARDATION; HEMATOLOGIC DISEASE; HUMAN; HYPERVISCOSITY SYNDROME; IATROGENIC DISEASE; LEUKEMIA; LEUKOENCEPHALOPATHY; LEUKOSTASIS; MENINGEAL METASTASIS; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROMYELOCYTIC LEUKEMIA; REVIEW; SEIZURE; TREATMENT OUTCOME; VASCULITIS;

BLOOD VISCOSITY; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; LEUKEMIA; LEUKEMIC INFILTRATION; LEUKOSTASIS; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; TOMOGRAPHY, X-RAY COMPUTED; VASCULITIS; VENOUS THROMBOSIS;

EID: 0036907470     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200212000-00006     Document Type: Review

References (44)

1. LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 2002; 20:237-46. A comprehensive evaluation with 9.2-year mean follow-up of 369 patients with ALL is reported.
2. Hashiguchi T, Tara M, Niina K, et al. Adult T-cell leukemia (ATL) cells which express neural cell adhesion molecule (NCAM) and infiltrate into the central nervous system. Intern Med 2002; 41:34-38.
3. Ravandi F, Cortes J, Estrov Z, et al. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 2002; 26:643-649.
4. Morrison C, Shah S, Flinn IW. Leptomeningeal involvement in chronic lymphocytic leukemia. Cancer Pract 1998; 6:223-228.
5. Glass JP, Van Tassel P, Keating MJ, et al. Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16. Neurology 1987; 37:639-644.
6. Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985; 65:1071-1078.
7. Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children (Children's Cancer Study Group A). Cancer 1970; 26:404-409.
8. Langer T, Martus P, Ottensmeier H, et al. CNS late-effects after ALL therapy in childhood. Part III: Neuropsychological performance in long-term survivors of childhood ALL: Impairments of concentration, attention, and memory. Med Pediatr Oncol 2002; 38:320-328. This paper reports a 7-year follow-up study of the neurologic performance of 121 patients who received both methotrexate and cranial irradiation for ALL.
9. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Olin Oncol 2002; 15:2464-2471. This important study details the rationale and approach for risk stratification based treatment in ALL patients.
10. Suprapaneni UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 2002; 94:773-779. This is a valuable descriptive retrospective review of 527 patients with ALL who achieved complete remission. Thirty-two of these patients were found to have CNS relapse and are described.
11. Millot F, Suciu S, Philippe N, et al. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Olin Oncol 2001; 19:1935-1942.
12. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: Results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16:1099-1111. This is a large, multicenter, prospective study of 462 patients with ALL treated without upfront cranial irradiation.
13. Kingma A, van Dommelen RI, Mooyaart EL, et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr 2001; 139:413-420. Important initial evaluations of neurocognitive function in children with ALL who received chemotherapy with CSI are reported.
14. Kingma A, van Dommelen RI, Mooyaart EL, et al. No major cognitive impairment in young children with acute lymphoblastic leukemia using chemotherapy only: A prospective longitudinal study. J Pediatr Hematol Oncol 2002; 24:106-114. This is a recent cognition study of pediatric ALL patients treated with chemotherapy only, conducted by the same investigators as [11].
15. Espy KA, Moore IM, Kaufmann PM, et al. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lympho-blastic leukemia: A prospective study. J Pediatr Psychol 2001; 26:1-9.
16. van den Berg H, Odink AE, Behrendt H. Delayed craniospinal irradiation for a first isolated central nervous relapse of acute lymphoblastic leukemia: Report on 14 cases. Med Pediatr Oncol 2000; 34:402-406.
17. Posner JP. Neurologic Complications of Cancer. Oxford: Oxford University Press; 1995. pp. 151-153.
18. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995; 38:51-57.
19. Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: Comparison of three sequences. AJNR Am J Neuroradiol 2002; 23:817-821. This is a well thought out comparison of OSF and MRI for the diagnosis of leptomeningeal metastasis.
20. Sze G. Leptomeningeal tumor: The 'plain vanilla' approach remains the best. AJNR Am J Neuroradiol 2002; 23:745-746.
21. Wirtz PW, Bloem BR, van der Meer FJ, Brouwer OF. Paraparesis after lumbar puncture in a male with leukemia. Pediatr Neurol 2000; 23:67-88.
22. Hansen PB, Kjeldsen L, Dalhoff K, Olesen B. Cerebrospinal fluid beta-2-microglobulin in adult patients with acute leukemia or lymphoma: A useful marker in early diagnosis and monitoring of CNS-involvement. Acta Neurol Scand 1992; 85:224-227.
23. Subira D, Castanon S, Aceituno E, et al. Flow cytometric analysis of cerebrospinal fluid samples and its usefulness in routine clinical practice. Am J Clin Pathol 2002; 117:952-958. This important study documents a valuable diagnostic tool.
24. Subira D, Castanon S, Roman A, et al. Flow cytometry and the study of central nervous disease in patients with acute leukaemia. Br J Haematol 2001; 112:381-384. This important study documents a valuable diagnostic tool.
25. Chamberlain MC, Kormanik PA, Glantz MJ. A comparison between ventricular and lumbar cerebrospinal fluid cytology in adult patients with leptomeningeal metastases. Neuro-oncology 2001; 3:42-45.
26. Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2002; 20:33-41. A detailed explanation of the molecular biology of this disease and how it affects coagulation chemistry is presented.
27. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 2001; 98:266-271.
28. Roberts TF, Sprague K, Schenkein D, et al. Hyperleukocytosis during induction therapy with arsenic trioxide for relapsed acute promyelocytic leukemia associated with central nervous system infarction. Blood 2000; 96:4000-4001.
29. Saito T, Koyama T, Nagata K, et al. Anticoagulant effects of retinoic acids on leukemia cells. Blood 1996; 87:657-865.
30. Lawrence JB, Yomotvian RA, Hammons T, et al. Lowering the prophylactic platelet transfusion threshold: A prospective analysis. Leuk Lymphoma 2001; 41:67-76. This carefully conducted study raises the threshold for platelet transfusion.
31. Benjamin RJ, Anderson KC. What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Crit Rev Oncol Hematol 2002; 42:163-171. This carefully conducted study raises the threshold for platelet transfusion.
32. Bick RL. Disseminated intravascular coagulation: A review of etiology, pathophysiology, diagnosis, and management: Guidelines for care. Clin Appl Thromb Hemost 2002; 8:1-31. A thorough and practical review of DIC by an expert in the field is presented.
33. Spivak JL. Erythropoietin use and abuse: When physiology and pharmacology collide. Adv Exp Med Biol 2001; 502:207-224.
34. Nowak-Gottl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93:1595-1599.
35. deBruijn SF, de Haan RJ, Stam J. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group. J Neurol Neurosurg Psychiatry 2001; 70:105-108.
36. Wermes C, Fleischhack G, Junker R, et al. Cerebral venous sinus thrombosis in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype and further prothrombotic risk factors. Klin Padiatr 1999; 211:211-214.
37. Nowak-Gottl U, Boos J, Wolff JE, et al. Asparaginase decreases clotting factors in vitro: A possible pitfall? Int J Clin Lab Res 1995; 25:146-148.
38. Hongo T, Okada S, Ohzeki T, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic leukemia: A retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int 2002; 44:293-299.
39. Paydas S, Zorludemir S, Sahin B. Vasculitis and leukemia. Leuk Lymphoma 2000; 40:105-112.
40. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy. Blood 2000; 95:2770-2775.
41. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002; 99:4257-4264.
42. Hisada M, Biggar RJ, Greene MH, et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98:1979-1981. This is an impressive descriptive study of 1820 secondary malignancies among 16 367 patients treated for CLL.
43. Garcia De Viedma D, Diaz Infantes M, Miralles P, et al. JC virus load in progressive multifocal leukoencephalopathy: Analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis 2002; 34:1568-1575.
44. Poulsen A, Schmiegelow K, Yssing M. Varicella zoster infections in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1996; 13:231-238.